NMI 921

Drug Profile

NMI 921

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator NitroMed
  • Class
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Female sexual dysfunction

Most Recent Events

  • 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
  • 13 Mar 2003 No development reported - Preclinical for Female sexual dysfunction in USA (Topical)
  • 24 Aug 2000 A preclinical study has been added to the Women's Health pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top